Circulating fibroblast growth factor 21 and growth differentiation factor 15 are associated with severity of hepatic steatosis in people with <scp>HIV</scp>
People with HIV and hepatic steatosis had higher levels of serum FGF21 and GDF15 than those without steatosis, and levels correlated with disease severity. FGF21 and GDF15 may aid in identifying people with HIV at risk of steatotic liver disease.
Authors
- Kate Ailstock
- Samer Gawrieh (ORCID: https://orcid.org/0000-0002-2056-4909)
- Ashok Balasubramanyam (ORCID: https://orcid.org/0000-0003-2093-5201)
- Nicholas Funderburg (ORCID: https://orcid.org/0000-0003-3113-1217)
- Kathleen E. Corey (ORCID: https://orcid.org/0000-0003-2882-7264)
- Paula Debroy (ORCID: https://orcid.org/0000-0001-9887-0300)
- Jordan E. Lake (ORCID: https://orcid.org/0000-0002-0640-5514)
- Sean M. Hartig (ORCID: https://orcid.org/0000-0002-2695-2072)
- Francis Pike
Institutions
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- Indiana University School of Medicine
- The Ohio State University (US)
- Indiana University – Purdue University Indianapolis (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- HIV Medicine
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1111/hiv.70060
- Citations
- 3
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 2.42